SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Follow-up) — Elvis Presley — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientElvis Presley
Date of birth1935-01-08
IdentifiersMRN HR-ML003-SYN-TD; SSN (made up) 000-03-4417
Document date1974-09-23
AuthorColeman Ashby-Nakagawa, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Ten-week review after the Las Vegas engagement and a back strain, before a three-week tour. [S]

History of Present Illness

Mr. Presley returns after a three-week engagement in Las Vegas and two weeks after the sick visit for a back strain. The back pain settled within a week on split buprenorphine doses and naproxen, and he has gone back to 16 mg once each morning. He took no other opioid and no extra diazepam. He had video visits in the first and third weeks of the engagement; the second was missed when a rehearsal ran late, and a nurse called him the next day. He used the travel CPAP on most nights. He has had mild nausea for a day after each tirzepatide dose and no constipation. His weight is 105.1 kg. His ophthalmologist saw him last week, found his eye pressures controlled on latanoprost and made no change. His HIV and hepatitis C tests were nonreactive and his hepatitis B tests showed no immunity. The tour begins in four days. [S]

ElementDetail
Buprenorphine16 mg daily; no other opioid; cravings rare
Diazepam36 mg a day since the three-week visit; no withdrawal symptoms
Back strainResolved
Tirzepatide2.5 mg weekly for six weeks; mild nausea for a day after each dose
Weight105.1 kg, down 3.9 kg from intake
OphthalmologyPressures controlled; no change
Screening resultsHIV and hepatitis C nonreactive; hepatitis B not immune

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy good
MusculoskeletalNegativeBack pain resolved
GastrointestinalPositiveMild nausea for a day after each injection; bowels regular
EyesNegativeNo pain or halos
PsychiatricNegativePHQ-9 5; no thoughts of suicide or self-harm

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Hydromorphone 4 mg oral tablet, prescribed elsewhere as one tablet every four to six hours as needed for back and neck pain; taking about five a day (20 mg, 100 MME); continued by this clinic only, at the verified dose and seven days at a time, until the addiction medicine consultationUp to five tablets a day; seven-day supplyOral route1974-07-10 to 1974-07-17completedS
Oxycodone 10 mg and acetaminophen 325 mg oral tablet, prescribed by a second prescriber; taking about three a day (45 MME); continued by this clinic only, seven days at a time, until the consultationUp to three tablets a day; seven-day supplyOral route1974-07-10 to 1974-07-17completedS
Diazepam 10 mg oral tablet, one tablet three times daily, prescribed elsewhere for anxiety; continued by this clinic only, seven days at a timeOne tablet three times daily; seven-day supplyOral route1974-07-10 to 1974-07-17completedS
Alprazolam 1 mg oral tablet, up to three a day as needed, prescribed by a fourth prescriber while on tour; continued by this clinic only, at the verified dose, seven days at a timeUp to three tablets a day; seven-day supplyOral route1974-07-10 to 1974-07-17completedS
Phentermine 37.5 mg oral tablet each morning, prescribed by a weight clinic; stopped today because of high blood pressure and his glaucomaStoppedOral route1974-07-10 to 1974-07-10completedS
Latanoprost 0.005% eye drops, one drop in each eye at bedtime, prescribed by his ophthalmologistOne drop in each eye at bedtimeOphthalmic route1974-07-10activeS
Naloxone 4 mg nasal spray, one spray into one nostril for a suspected overdose, repeated in the other nostril after two to three minutes if needed; two-pack, with a second for the tour bagOne spray for a suspected overdose; call 911Nasal route1974-07-10activeS
Polyethylene glycol 3350, 17 g powder in a glass of water once daily17 g in water once dailyOral route1974-07-10activeS
Senna 8.6 mg oral tablet, two tablets at bedtimeTwo tablets at bedtimeOral route1974-07-10 to 1974-08-07completedS
Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily, which may be split into one film twice daily; started in the office at the consultation; seven-day supplies at first, from this clinic onlyTwo films once daily, or one film twice dailySublingual route1974-07-17activeS
Diazepam 10 mg oral tablet, one tablet four times daily (40 mg a day), replacing both diazepam 10 mg three times daily and alprazolam; held steady until buprenorphine is stableOne tablet four times daily; seven-day supplyOral route1974-07-17 to 1974-08-07completedS
Diazepam 10 mg oral tablet, one tablet three times daily, with diazepam 2 mg tablets for the taper steps; dispensed two weeks at a timeOne tablet three times daily with the 2 mg tablets as scheduledOral route1974-08-07activeS
Diazepam 2 mg oral tablet on the written taper schedule: three a day (36 mg a day in all) from the three-week visit, one a day (32 mg) from the ten-week visit, stopped at four months (30 mg)Per the written taper scheduleOral route1974-08-07 to 1974-10-28completedS
Amlodipine 5 mg and valsartan 160 mg oral tablet, one tablet dailyOne tablet dailyOral route1974-07-17activeS
Tirzepatide 2.5 mg/0.5 mL auto-injector, 2.5 mg under the skin once weekly2.5 mg once weeklySubcutaneous route1974-08-07 to 1974-09-23completedS
Tirzepatide 5 mg/0.5 mL auto-injector, 5 mg under the skin once weekly5 mg once weeklySubcutaneous route1974-09-23activeS
Naproxen 500 mg oral tablet, one tablet twice daily with food for five daysOne tablet twice daily with food for five daysOral route1974-09-09 to 1974-09-13completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1974-09-23Body height183cmS
1974-09-23Body weight105.1kgS
1974-09-23Body mass index (BMI) [Ratio]31.4kg/m2S
1974-09-23Systolic blood pressure126mm[Hg]S
1974-09-23Diastolic blood pressure80mm[Hg]S
1974-09-23Heart rate74/minS
1974-09-23Respiratory rate14/minS
1974-09-23Body temperature36.6CelS
1974-09-23Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1974-09-23Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
1974-09-23Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]7{score}S

Physical Exam

Vital signs recorded on 1974-09-23; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 126/80, pulse 74; weight 105.1 kg, BMI 31.4
BackFull, painless range of motion
NeurologicalNo tremor or sedation

Problems

ProblemClinical statusVerificationCodeProvenance
Fatigue, weight gain of about 14 kg in two years, constipation with a bowel movement every five to seven days, loud snoring with daytime sleepiness, and high blood pressure readings, in a man taking two opioids, two benzodiazepines and an appetite suppressant from five prescribers; under evaluation with addiction medicine, a sleep study and home blood pressure readingsresolvedconfirmed R53.83S — Synthetic presenting problem anchored to the documented prescribed drugs and weight gain; superseded when the consultation and tests made the diagnoses.
Obesity, class 1 (BMI 32.5), with prediabetes (hemoglobin A1c 5.8%); recorded without stigma; weight gain began with long touring schedules, night eating after shows and an appetite suppressant that stopped workingactiveconfirmed E66.811S — Synthetic modern diagnosis anchored to his documented weight gain.
Glaucoma secondary to steroids, both eyes, mild stage, after an acute angle-closure episode treated years ago; intraocular pressure controlled on latanoprost under his ophthalmologist; anticholinergic and sympathomimetic drugs to be avoidedactiveconfirmed H40.63X1S — Synthetic modern diagnosis anchored to his documented glaucoma and the retrospective interpretation of it as steroid-induced; not a claim about his real eyes.
Opioid use disorder, severe, with prescription opioids from more than one prescriber (seven DSM-5-TR criteria, tolerance and withdrawal counted because the opioids were not taken as prescribed); on buprenorphine from the consultation; synthetic modern episode linked to his documented withdrawal from narcotic drugs and prescribed painkillersactiveconfirmed F11.20S — Synthetic modern diagnosis made at the addiction medicine consultation; person-first language; not a claim about his real diagnosis.
Sedative, hypnotic, or anxiolytic use disorder (benzodiazepines), moderate (five DSM-5-TR criteria), with two benzodiazepines from two prescribers; combined into diazepam and tapering slowly; synthetic modern episode linked to his documented prescribed sedativesactiveconfirmed F13.20S — Synthetic modern diagnosis made at the consultation; not a claim about his real diagnosis.
Hypertension, stage 2, confirmed by a home average of 146/94 a week after stopping phentermine; ECG and urine albumin normalactiveconfirmed I10S — Synthetic modern diagnosis confirmed with home readings, anchored to his documented hypertension.
Obstructive sleep apnea, moderate (apnea-hypopnea index 26 an hour, central apnea index 4, oxygen nadir 80% on in-laboratory polysomnography), worsened by opioids and benzodiazepines; on CPAPactiveconfirmed G47.33S — Synthetic modern diagnosis from a synthetic sleep study.
Opioid-induced constipation (Rome IV), improving after the change to buprenorphine; no alarm featuresactiveconfirmed K59.03S — Synthetic modern diagnosis anchored to his documented blockage of the colon; not a claim about megacolon.
Acute low back strain after karate practice, without radicular signs or red flags, in a man on buprenorphine; resolvedresolvedconfirmed S39.012AS — Synthetic acute injury; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Medication safetyBuprenorphine dose, withdrawal symptoms, cravings and other opioid useEvery visit; weekly contact in the first monthCompleted today16 mg daily; split dosing for one week during the back strain; no other opioid
SurveyWeekly video visits while awayWeekly during engagements and toursDeferredThe second weekly video visit in Las Vegas was missed when a rehearsal ran late; a nurse reached him by phone the next day and found him well. No harm resulted. Corrective action: a fixed weekly time on tour with a backup slot the same day
Medication safetyPrescription drug monitoring program checkBefore every controlled-substance prescriptionCompleted todayOnly this clinic's prescriptions, filled at the named pharmacies
LaboratoryUrine drug test, including buprenorphine metabolite and fentanylAt the start of treatment, then about monthly while doses are changingCompleted todayCollected at the start of the visit: buprenorphine, norbuprenorphine and benzodiazepines present; no other opioid; fentanyl absent (narrative)
Medication safetyNaloxone on hand and people taught to use itEvery visitCompleted todayIn the tour bag; two people trained
Medication safetyDiazepam dose, withdrawal symptoms (anxiety, insomnia, tremor, sweats) and taper paceEvery two to four weeks during the taperCompleted today36 to 32 mg a day (11%) after six weeks at 36 mg; no withdrawal symptoms
SurveySuicide-risk review, safety plan, means safety (locked medicines and firearms) and the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; firearms and medicines locked
SurveyMood (PHQ-9) and anxiety (GAD-7)At each reviewCompleted todayPHQ-9 5 (item 9 scored 0); GAD-7 7
ExaminationOffice and home blood pressure (target below 130/80)Every visitCompleted todayOffice 126/80; home average 124/80
LaboratoryPotassium and creatinine after starting an angiotensin receptor blockerTwo to four weeks after starting, then every six monthsUp to dateNormal three weeks after starting; next at six months
ExaminationWeight and BMIEvery visitCompleted today105.1 kg, BMI 31.4; down 3.9 kg
Medication safetyTirzepatide tolerance: nausea, vomiting, constipation, abdominal painAt each dose stepCompleted todayMild nausea for a day after each dose; no vomiting or constipation; increased to 5 mg
SurveyCPAP adherence (device data) and sleepiness (Epworth, recorded as narrative)Within the first 30 to 90 days, then at each reviewCompleted today86% of nights over the engagement; Epworth 7
Self-managementBowel frequency, straining and alarm featuresEvery visitCompleted todayDaily or every other day on polyethylene glycol
ExaminationGlaucoma: drop adherence, eye symptoms, medicines that raise eye pressure or close the angle, and ophthalmology follow-upEvery visit; ophthalmology every three to six months while recently controlledCompleted todayOphthalmology last week: pressures controlled, no change; no new drug that affects eye pressure
Self-managementTouring plan: one named pharmacy, video visits while away, CPAP and naloxone in the tour bag, no dose change in the week before an engagementBefore each engagement or tourCompleted todayTour plan written: named pharmacy chain, fixed video visit time with backup, travel CPAP, naloxone

Goal progress:

Immunizations given today: Hepatitis B vaccine (HepB-CpG), first of two doses, after serology showed no immunity [S]

Guideline basis: CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022); The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity (2022); Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline (2019); Primary Open-Angle Glaucoma Preferred Practice Pattern (2020); Adult Immunization Schedule by Age (2026)

Follow-up: First hepatitis B vaccine dose given today. Weekly video visits on tour. Four-month review after the tour. Next scheduled visit 1974-10-28: four-month review after the tour: recovery, the taper, blood pressure, weight, liver tests, sleep and the plan ahead. [S]